| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Investigations |
University of Nottingham Laboratory of Molecular Oncology, Cancer Research Campaign Department of Clinical Oncology [J. D. W., P. W. H, D. K., J. C., J. C. M.] and Department of Histopathology [T. M.], Nottingham City Hospital, Nottingham NG5 1PB, United Kingdom, and Molecular/Cancer Biology Laboratory, Haartman Institute, University of Helsinki, SF-00014 Helsinki, Finland [B. C. E.]
The angiogenic factor vascular endothelial growth factor-D (VEGF-D) isa ligand for VEGF receptor-3 (VEGFR-3/Flt-4) and receptor-2 (VEGFR-2/KDR)and is implicated in the development of lymphatic vessels and promotion of lymphatic metastases. We assessed the expression of VEGF-D and VEGFR-3 in relation to microvessel density (MVD) in colorectal carcinomas (CRC), adenomas, and adjacent normal tissue by immunohistochemistry on consecutive archival sections. VEGF-D was detected in malignant and benign epithelium and in some smooth muscle of the colorectum. High-grade VEGF-D expression was observed frequently (74%) in CRC compared with adenomas (0%) and adjacent normal mucosa (22%). High-grade VEGF-D expression was not correlated with MVD, Dukes’ stage (A to C), or tumor differentiation, but was associated with lymphatic involvement and patient survival. By multivariate analysis, VEGF-D expression was found to be an independent prognostic factor for both disease-free and overall survival. VEGFR-3 expression was detected in a subset of vessels, typically thin-walled and devoid of RBCs, in 89% of CRC cases examined. VEGFR-3-positive vessel densities increased progressively from normal mucosa to adenomas and carcinomas and were correlated with MVD, but not with Dukes’ stage (A to C), tumor differentiation, or VEGF-D expression. VEGFR-3 expression was spatially associated with macrophage-rich inflammatory infiltrates, which were significantly more frequent among VEGFR-3-positive cases. We conclude that VEGF-D expression, but not that of its receptor VEGFR-3, is an independent prognostic indicator in CRC. VEGF-D expression may be associated with disease outcome through the promotion of lymphatic involvement/metastases.
This article has been cited by other articles:
|
|
 |
|
  K. Dahl, M. Karlsson, P. Marits, A. Hoffstedt, O. Winqvist, and M. Thorn Metinel Node--The First Lymph Node Draining a Metastasis--Contains Tumor-Reactive Lymphocytes Ann. Surg. Oncol., May 1, 2008; 15(5): 1454 - 1463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. ACHEN and S. A. STACKER Molecular Control of Lymphatic Metastasis Ann. N.Y. Acad. Sci., May 1, 2008; 1131(1): 225 - 234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Kim, Y. S. Chae, S. K. Sohn, Y. Y. Cho, J. H. Moon, J. Y. Park, S. W. Jeon, I. T. Lee, G. S. Choi, and S.-H. Jun Vascular Endothelial Growth Factor Gene Polymorphisms Associated with Prognosis for Patients with Colorectal Cancer Clin. Cancer Res., January 1, 2008; 14(1): 62 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Donnem, S. Al-Saad, K. Al-Shibli, M. P. Delghandi, M. Persson, M. N. Nilsen, L.-T. Busund, and R. M. Bremnes Inverse Prognostic Impact of Angiogenic Marker Expression in Tumor Cells versus Stromal Cells in Non Small Cell Lung Cancer Clin. Cancer Res., November 15, 2007; 13(22): 6649 - 6657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Kopfstein, T. Veikkola, V. G. Djonov, V. Baeriswyl, T. Schomber, K. Strittmatter, S. A. Stacker, M. G. Achen, K. Alitalo, and G. Christofori Distinct Roles of Vascular Endothelial Growth Factor-D in Lymphangiogenesis and Metastasis Am. J. Pathol., April 1, 2007; 170(4): 1348 - 1361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Chen, M. E. Rose, H. Hwang, R. G. Nines, and G. D. Stoner Black raspberries inhibit N-nitrosomethylbenzylamine (NMBA)-induced angiogenesis in rat esophagus parallel to the suppression of COX-2 and iNOS Carcinogenesis, November 1, 2006; 27(11): 2301 - 2307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Shayan, M. G. Achen, and S. A. Stacker Lymphatic vessels in cancer metastasis: bridging the gaps Carcinogenesis, September 1, 2006; 27(9): 1729 - 1738. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Miyata, S. Kanda, K. Ohba, K. Nomata, Y. Hayashida, J. Eguchi, T. Hayashi, and H. Kanetake Lymphangiogenesis and Angiogenesis in Bladder Cancer: Prognostic Implications and Regulation by Vascular Endothelial Growth Factors-A, -C, and -D Clin. Cancer Res., February 1, 2006; 12(3): 800 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Juttner, C. Wissmann, T. Jons, M. Vieth, J. Hertel, S. Gretschel, P. M. Schlag, W. Kemmner, and M. Hocker Vascular Endothelial Growth Factor-D and Its Receptor VEGFR-3: Two Novel Independent Prognostic Markers in Gastric Adenocarcinoma J. Clin. Oncol., January 10, 2006; 24(2): 228 - 240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Tanaka, A Tatsuguchi, S Futagami, K Gudis, K Wada, T Seo, K Mitsui, M Yonezawa, K Nagata, S Fujimori, et al. Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma Gut, January 1, 2006; 55(1): 54 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Pradeep, E. S. Sunila, and G. Kuttan Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Tumor Angiogenesis and Malignancies Integr Cancer Ther, December 1, 2005; 4(4): 315 - 321. [Abstract] [PDF]
|
|
|
|
 |
|
 W. Debinski and D. M. Gibo Fos-Related Antigen 1 Modulates Malignant Features of Glioma Cells Mol. Cancer Res., April 1, 2005; 3(4): 237 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Jimenez, D. Lu, L. Brennan, K. Persaud, M. Liu, H. Miao, L. Witte, and Z. Zhu A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3 Mol. Cancer Ther., March 1, 2005; 4(3): 427 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Kaushal, P. Mukunyadzi, R. A. Dennis, E. R. Siegel, D. E. Johnson, and M. Kohli Stage-Specific Characterization of the Vascular Endothelial Growth Factor Axis in Prostate Cancer: Expression of Lymphangiogenic Markers Is Associated with Advanced-Stage Disease Clin. Cancer Res., January 15, 2005; 11(2): 584 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kurahara, S. Takao, K. Maemura, H. Shinchi, S. Natsugoe, and T. Aikou Impact of Vascular Endothelial Growth Factor-C and -D Expression in Human Pancreatic Cancer: Its Relationship to Lymph Node Metastasis Clin. Cancer Res., December 15, 2004; 10(24): 8413 - 8420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hoeben, B. Landuyt, M. S. Highley, H. Wildiers, A. T. Van Oosterom, and E. A. De Bruijn Vascular Endothelial Growth Factor and Angiogenesis Pharmacol. Rev., December 1, 2004; 56(4): 549 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Sipos, W. Klapper, M.-L. Kruse, H. Kalthoff, D. Kerjaschki, and G. Kloppel Expression of Lymphangiogenic Factors and Evidence of Intratumoral Lymphangiogenesis in Pancreatic Endocrine Tumors Am. J. Pathol., October 1, 2004; 165(4): 1187 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Fox, J. Braganca, H. Turley, L. Campo, C. Han, K. C. Gatter, S. Bhattacharya, and A. L. Harris CITED4 Inhibits Hypoxia-Activated Transcription in Cancer Cells, and Its Cytoplasmic Location in Breast Cancer Is Associated with Elevated Expression of Tumor Cell Hypoxia-Inducible Factor 1{alpha} Cancer Res., September 1, 2004; 64(17): 6075 - 6081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Emanuel, R. H. Gruninger, A. Fuentes-Pesquera, P. J. Connolly, J. A. Seamon, S. Hazel, R. Tominovich, B. Hollister, C. Napier, M. R. D'Andrea, et al. A Vascular Endothelial Growth Factor Receptor-2 Kinase Inhibitor Potentiates the Activity of the Conventional Chemotherapeutic Agents Paclitaxel and Doxorubicin in Tumor Xenograft Models Mol. Pharmacol., September 1, 2004; 66(3): 635 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M J Currie, V Hanrahan, S P Gunningham, H R Morrin, C Frampton, C Han, B A Robinson, and S B Fox Expression of vascular endothelial growth factor D is associated with hypoxia inducible factor (HIF-1{alpha}) and the HIF-1{alpha} target gene DEC1, but not lymph node metastasis in primary human breast carcinomas J. Clin. Pathol., August 1, 2004; 57(8): 829 - 834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zeng, K. Opeskin, M. E. Baldwin, L. G. Horvath, M. G. Achen, S. A. Stacker, R. L. Sutherland, and E. D. Williams Expression of Vascular Endothelial Growth Factor Receptor-3 by Lymphatic Endothelial Cells Is Associated with Lymph Node Metastasis in Prostate Cancer Clin. Cancer Res., August 1, 2004; 10(15): 5137 - 5144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. P. Padera, Y. Boucher, R. K. Jain, L. M. Wein, P. E. Holden, and D. H. Kirn Correspondence re: S. Maula et al., Intratumoral Lymphatics Are Essential for the Metastatic Spread and Prognosis in Squamous Cell Carcinoma of the Head and Neck. Cancer Res., 63: 1920-1926, 2003. Cancer Res., December 1, 2003; 63(23): 8555 - 8557. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Orlandini, S. Semboloni, and S. Oliviero {beta}-Catenin Inversely Regulates Vascular Endothelial Growth Factor-D mRNA Stability J. Biol. Chem., November 7, 2003; 278(45): 44650 - 44656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Boedefeld II, K. I. Bland, and M. J. Heslin Recent Insights Into Angiogenesis, Apoptosis, Invasion, and Metastasis in Colorectal Carcinoma Ann. Surg. Oncol., October 1, 2003; 10(8): 839 - 851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. K. McColl, M. E. Baldwin, S. Roufail, C. Freeman, R. L. Moritz, R. J. Simpson, K. Alitalo, S. A. Stacker, and M. G. Achen Plasmin Activates the Lymphangiogenic Growth Factors VEGF-C and VEGF-D J. Exp. Med., September 15, 2003; 198(6): 863 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Ruggeri, J. Singh, D. Gingrich, T. Angeles, M. Albom, H. Chang, C. Robinson, K. Hunter, P. Dobrzanski, S. Jones-Bolin, et al. CEP-7055: A Novel, Orally Active Pan Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models Cancer Res., September 15, 2003; 63(18): 5978 - 5991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yokoyama, D. S. Charnock-Jones, D. Licence, A. Yanaihara, J. M. Hastings, C. M. Holland, M. Emoto, A. Sakamoto, T. Sakamoto, H. Maruyama, et al. Expression of Vascular Endothelial Growth Factor (VEGF)-D and Its Receptor, VEGF Receptor 3, as a Prognostic Factor in Endometrial Carcinoma Clin. Cancer Res., April 1, 2003; 9(4): 1361 - 1369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. DEBINSKI, D. GIBO, and A. MINTZ Epigenetics in High-Grade Astrocytomas: Opportunities for Prevention and Detection of Brain Tumors Ann. N.Y. Acad. Sci., March 1, 2003; 983(1): 232 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nakamura, H. Yasuoka, M. Tsujimoto, Q. Yang, S. Imabun, M. Nakahara, K. Nakao, M. Nakamura, I. Mori, and K. Kakudo Prognostic Significance of Vascular Endothelial Growth Factor D in Breast Carcinoma with Long-Term Follow-Up Clin. Cancer Res., February 1, 2003; 9(2): 716 - 721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Straume, D. G. Jackson, and L. A. Akslen Independent Prognostic Impact of Lymphatic Vessel Density and Presence of Low-Grade Lymphangiogenesis in Cutaneous Melanoma Clin. Cancer Res., January 1, 2003; 9(1): 250 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Jain and T. P. Padera Prevention and Treatment of Lymphatic Metastasis by Antilymphangiogenic Therapy J Natl Cancer Inst, June 5, 2002; 94(11): 785 - 787. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
